Historically, when several versions of a physician-administered drug (for example, biologic and one or more biosimilar products) are available, hospital pharmacy and therapeutics (P&T) committees ...

Remember, biosimilars are like the original drug. They have been tested to make sure they work in the same way. Your doctor or pharmacist can answer any specific questions you have. They will give you ...

Again using generics as an example, patients initially were skeptical as they were concerned that these products were lesser than the branded drugs they may have already been taking. Biosimilars ...

For example, CVS could absorb a portion of a biosimilar manufacturer’s profit margin, Fein wrote in an article posted on the Drug Channels website. Other examples include establishing ...

for example, an animal cell or microorganism. The first biological medicine to be approved for use in the European Union for a particular condition is called the biological reference medicine. A ...

To move this biosimilar into clinical trials, though, industrial scientists would need more thorough testing, including toxicology studies. As this example shows, a long path lies between any ...

The number of new prescriptions written for biosimilar versions of the Humira rheumatoid arthritis treatment, one of the best-selling medicines in the U.S., surged to 36% from just 5% during the ...

Hadlima was approved as a biosimilar to Humira in 2019 ... health care system through this collaboration, which is a great example of industry and public sector working together,” Ali added.

For example, when Biocon and Viatris launched their interchangeable insulin biosimilar, Semglee, with two different prices, many payers didn’t even offer the lower-priced version. Meanwhile ...

But there are key players who are not on board with biosimilars. And their reticence could hinder the uptake of these lower-cost knockoffs. For example, a study last month showed (PDF) that ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter ...